title: Results from an international multicenter trial evaluating the ease-of-use of and preference for a newly developed disposable injection pen for the treatment of growth hormone deficiency in treatment-naïve children and adults.
abstract: Previous research has reported that ease of use of and preference for a delivery device are associated with greater patient compliance - an important factor in achieving optimal therapeutic results. The objective of this study was to assess the ease-of-use of a new disposable pen (GoQuick(®), Pfizer, Inc.) versus the current reusable pen (GENOTROPIN Pen(®), Pfizer, Inc.) to inject a daily dose of recombinant DNA origin human growth hormone, Genotropin(®) (somatropin) in standard practice. In this randomized, crossover, multicenter, multinational, open-label study, ease-of-use of and preference for the two pens were assessed in three treatment-naïve populations: 1) parents of very young children; 2) parent-child dyads; and 3) adults via use of a validated self-report Injection Pen Assessment Questionnaire (IPAQ) after 2 months of at-home-use experience. The primary endpoint was the proportion of participants who reported the new disposable pen to be no different from or easier to use than the current reusable pen. Safety was also assessed and reported according to local legal requirements. Of the 120 screened patients, 119 were included in the ease-of-use analysis and all were included in the safety analyses. In all, 67.2% found the new somatropin disposable pen to be no different from or easier to use than the reusable pen (95% confidence interval: 58.8-75.7). Most adverse events were mild or moderate. No deaths or device- or treatment-related serious adverse events were reported. These results suggest that improvements made to the reusable somatropin pen are tangible and recognizable to treatment-naïve patients and their caregivers, child-caregiver dyads, and adults, and may positively impact continued compliance with therapy.
  ClinicalTrials.gov identifier: NCT01112865.
authors.affiliation: Pfizer Inc., San Diego, CA, USA.
authors.forename: Andreas M
authors.initials: AM
authors.lastname: Pleil
authors.affiliation: Istanbul Faculty of Medicine, Pediatric Endocrinology Unit, Capa, İstanbul, Turkey.
authors.forename: Feyza
authors.initials: F
authors.lastname: Darendeliler
authors.affiliation: Department of Pediatrics, University of Erlangen, Erlangen, Germany.
authors.forename: Helmuth G
authors.initials: HG
authors.lastname: Dörr
authors.affiliation: Quanticate, Hitchin, UK.
authors.forename: Katherine
authors.initials: K
authors.lastname: Hutchinson
authors.affiliation: Pfizer Ltd, Walton Oaks, UK.
authors.forename: Hartmut A
authors.initials: HA
authors.lastname: Wollmann
keywords: Injection Pen Assessment Questionnaire; disposable injection pen; ease-of-use; preference; recombinant human growth hormone; somatropin
references.citation: J Pediatr Endocrinol Metab. 2001 May;14(5):497-501
references.pmid: 11393569
references.citation: Horm Res. 1999;51 Suppl 3:109-12
references.pmid: 10592453
references.citation: Patient Prefer Adherence. 2013 May 24;7:455-62
references.pmid: 23737664
references.citation: Clin Ther. 2009 Dec;31(12):2906-14
references.pmid: 20110030
references.citation: J Pediatr Endocrinol Metab. 2011;24(7-8):489-96
references.pmid: 21932587
references.citation: Acta Paediatr Suppl. 1995 Sep;411:63-5
references.pmid: 8563072
references.citation: Med Devices (Auckl). 2013 Sep 02;6:141-6
references.pmid: 24039458
references.citation: Value Health. 2005 Mar-Apr;8(2):94-104
references.pmid: 15804318
references.citation: Health Qual Life Outcomes. 2012 Oct 09;10:126
references.pmid: 23046797
references.citation: J Pediatr Endocrinol Metab. 2003 Mar;16(3):383-92
references.pmid: 12705363
references.citation: BMC Endocr Disord. 2006 Oct 11;6:5
references.pmid: 17034628
references.citation: Clin Ther. 2010 Nov;32(12):2036-47
references.pmid: 21118739
references.citation: Arch Pediatr Adolesc Med. 2002 Mar;156(3):230-40
references.pmid: 11876666